BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management
Data Show Disparities in HMA Use Among Myelodysplastic Syndrome Populations
FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2– Breast Cancer
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
